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Abstract
To evaluate the effects of inflammatory bowel diseases 
(IBDs) on human reproduction, we reviewed the cur-
rent literature using a systematic search for published 
studies (articles and/or abstracts) without limits for 
English language. We searched on Medline (through 
PubMed), the Institute for Scientific Information, the 
Web of Science and the websites for the registration 
of controlled trials (http://controlled-trials.com/). Bib-
liographies of retrieved articles, books, expert opinion 
review articles and reviewed bibliographies from sub-
ject experts were manually searched. Titles and ab-
stracts were screened initially, and potential relevant 
articles were identified and reviewed. Whenever pos-
sible, data were analyzed by comparing IBD patients 
vs  healthy controls, and patients with active IBDs vs  
those with disease in remission. The effects of IBDs 
on female fertility, fertility in infertile couples, preg-
nancy and male infertility were examined separately. 
Patients with IBDs in remission have normal fertility. 
At the moment, there is no established guideline for 
the preservation of fertility in women with IBD un-
dergoing surgery. Further data are needed regarding 
guidelines for the management of these patients. Data 
regarding IBDs and infertility are currently completely 
lacking. Considering the prevalence of intestinal pa-
thology in young adults of childbearing age, this field 
is of great scientific and clinical interest, opening up 
important future perspectives. Another important and 
as yet unexplored point is the response to treatments 
for infertility in patients with IBDs. In particular, the 
question is whether the reproductive outcomes (clinical 
and biological) can be influenced by the IBD of one 
of the partners. The goals for successful reproductive 
outcomes in IBD population are correct counseling 
and disease remission. IBDs significantly affect several 
reproductive aspects of human (female, male, couple) 
reproduction. Further data are needed to develop 
guidelines for the clinical management of subjects of 
reproductive age with IBDs. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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INTRODUCTION
Inflammatory bowel diseases (IBDs) predominantly 
affect younger patients of  reproductive age. To date, 
several reviews[1-4] have been published in the English lit-
erature whose aim was to evaluate and clarify the impact 
on obstetric outcomes of  both the IBDs themselves and 
the drugs commonly used to treat them. However, very 
little is known on the overall effect of  IBDs on human 
reproduction.
The study of  human reproduction includes not only 
the effects of  IBDs and their treatment on pregnancy but 
also their effects on the menstrual cycle and hormonal 
patterns, on the subfertile women scheduled for ovula-
tion induction cycles or assisted reproductive techniques 
(ARTs), on future reproductive potential in younger and/
or adolescent women, and on male fertility, including data 
on semen parameters and libido/hormonal patterns.
Based on these considerations, the current study was 
designed to provide an evidence-based overview on the 
effects of  IBDs on all aspects of  human reproduction, 
including both female and male fertility, and to provide a 
critical synthesis useful for clinical practice.
SEARCH STRATEGY
To obtain evidence-based data and to provide evidence-
based recommendations, a systematic search for studies 
(articles and/or abstracts), without English language limi-
tation, was performed. 
It included the combination of  the following medi-
cal subject headings or keywords: “assisted reproduction 
techniques”, “ART”, “Crohn’s disease”, “complication”, 
“effectiveness”, “efficacy”, “embryo”, “endometrium”, 
“fertility”, “fetal”, “foetal”, “infertility”, “inflammatory 
bowel disease(s)”, “IBD(s)”, “intracytoplasmic insemi-
nation”, “ICSI”, “in vitro fertilization”, “IVF”, “libido”, 
“management”, “menstrual cycle”, “menses”, “neona-
tal”, “obstetrics”, “ovary”, “pregnancy”, “prevention”, 
“safety”, “semen analysis”, “sex hormones”, “sperm”, 
“spermatozoa”, “subfertility”, “surgery”, “therapy”, 
“treatment”, “UC”, “ulcerative colitis”.
We searched on Medline (through PubMed), the 
Institute for Scientific Information , the Web of  Sci-
ence, and the websites for the registration of  controlled 
trials (http://controlled-trials.com/). Bibliographies of  
retrieved articles, books, expert opinion review articles, 
and reviewed bibliographies from subject experts were 
manually searched. Titles and abstracts were screened ini-
tially, and potentially relevant articles were identified and 
reviewed
For each issue, we analyzed mainly meta-analyses 
and/or randomized controlled trials (RCTs). When meta-
analytic data or data from RCTs were lacking, prospective 
non-randomized and then cohort studies were included 
in the final analysis. 
To construct a comprehensive review, data regarding 
both primary endpoints, as traditionally suggested by 
evidence-based medicine (pragmatic view), and inter-
mediate endpoints, crucial to understanding the mecha-
nisms of  action (mechanistic view), were extrapolated 
and analyzed. 
Whenever possible, data were analyzed by comparing 
IBD patients vs healthy controls, and patients with active 
IBDs vs those with disease in remission.
FEMALE FERTILITY
Women with inactive Crohn’s disease (CD) or ulcerative 
colitis (UC) appear to have normal fertility. In remis-
sion, female fertility seems not to be diminished. A case-
control study by Elbaz et al[5] showed that there was an in-
creased need for fertility treatment of  women with IBD; 
however, this association was no longer significant after 
controlling for maternal age (increasing maternal age is 
associated with subfertility).
In CD, fertility is normal or slightly reduced[6-8]; 
older referral center studies estimated infertility rates of  
32%-42%[8-11], but community-based and population-
based studies suggest infertility rates of  5%-14%, similar 
to that of  the general population[7]. Women with UC have 
normal fertility until they undergo surgery[9,10]. 
Several reasons for the potentially reduced fertility in 
IBD women have been hypothesized. We have identified 
two main sources: psychological problems and surgery-
related problems. 
Psychological problems
Relatively few data are available regarding sexual dysfunc-
tions in women with IBD. Moody et al[12] did not find any 
significant change in rates of  dyspareunia and overall fre-
quency of  sexual intercourse between women with IBD 
and matched controls. On the other hand, a mismatch 
of  perception and reality seems to significantly affect 
family planning decisions in women with IBD. A recent 
large study[13] was published whose aim was to evaluate 
whether, and to what extent, IBD patients’ perceptions 
of  risk influence their reproductive behavior and to de-
scribe IBD patients’ specific concerns related to fertility 
and pregnancy. “Voluntary childlessness” was the main 
cause of  the reduced fertility rate (number of  live births 
per woman) reported in IBD patients[13]. This fear of  
infertility was most evident in women with CD and pre-
Palomba S et al . Inflammatory bowel diseases and reproduction
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vious surgery[13]. In particular, IBD-related reproductive 
risks seemed to be overestimated by the examined sub-
jects. The main reproductive concerns of  IBD patients 
regarded pregnancy risks, drug-related teratogenicity or 
toxicity, long-term risks and IBD inheritance[13]. 
Surgery-related problems
Women with active CD have decreased fertility[6], perhaps 
related to the formation of  adhesions caused by the dis-
ease itself  and/or surgery, resulting in tubal infertility[14]. 
Fertility may normalize after induction of  remission in 
women with CD[15]. Some surgical procedures, such as 
rectal excision and pouch formation, appear to have det-
rimental effects on male and female fertility. 
In UC with ileal pouch anal anastomosis (IPAA), the 
ability to become pregnant is significantly reduced, prob-
ably because of  the presence of  post-surgical adhesions 
in the pelvis, secondary obstruction of  the fallopian tubes 
or altering the normal tubo-ovarian relationship neces-
sary for ovum capture and transport[16-18]. Two studies 
that evaluated the impact of  proctocolectomy with pelvic 
pouch or end ileostomy on pelvic anatomy, showed that 
50 percent of  females had complete unilateral or bilateral 
obstruction of  the fallopian tubes[19,20]. These studies sug-
gested that pelvic dissection is the likely cause of  adhe-
sions and altered pelvic anatomy.
A systematic review showed that IPAA for UC re-
sults in decreased fertility[21]. The conception rate in 
women with UC was 40% before IPAA and only 29% 
after IPAA[21]. A meta-analysis estimated that the risk of  
infertility after IPAA increased by a factor of  three[22]. 
The high use of  fertility treatments after IPAA compared 
with other groups illustrates the difficulty these women 
have in getting pregnant after surgery. Olsen et al[10] 
found that after IPAA, 29% of  children were born after 
in vitro fertilization compared with only 1% in the general 
population. Another study[10] of  Danish and Swedish 
patients found that females had significantly decreased 
fecundity (probability of  becoming pregnant per month 
of  unprotected intercourse) after IPAA compared with 
before IPAA. The data regarding fertility after IPAA do 
not state the number of  women who voluntarily chose 
not to become pregnant and the impact of  age on female 
fertility, which could greatly influence the interpretation 
of  the results.
In a Canadian study, Johnson et al[23] confirmed that 
the infertility rate was significantly higher in IPAA pa-
tients compared with patients managed non-operatively 
(38.6% vs 13.3%). In that study, the effect of  age on the 
risk of  becoming pregnant was investigated for all pa-
tients who attempted to become pregnant in both the 
IPAA and non-operative management groups. There was 
a negative association between advancing age and suc-
cess of  becoming pregnant: for each additional year of  
age there was a 12% decrease in the odds of  becoming 
pregnant[23]. Increasing age was associated with decreased 
reproductive ability among all females included in that 
study[23].
A recent Finnish study showed that, although the 
probability of  a women conceiving in any short time 
period seemed to be reduced to 47% of  the average, 
the lifetime chance of  having at least one live birth after 
IPAA was 80%[24]. Thus, women with IPAA mostly suffer 
a reduction in the probability of  conception rather than 
complete infertility.
Strategies are needed to improve fertility after IPAA. 
One possibility would be to perform sub-total colec-
tomy/end ileostomy and delay IPAA, but this would 
likely be unacceptable to most females. A second strategy 
would be to preserve tubal patency and normal tubo-
ovarian relationship. Various materials are available to 
prevent post-surgical adhesions in the pelvis; however, 
as there are no data regarding their efficacy in improving 
fertility, further research is needed[25].
To date, there are no established guidelines for the 
preservation of  fertility in women with IBD undergoing 
surgery. However, we believe that an effective strategy 
should be based on the following principles: (1) proper 
selection of  patients with a specific clinical indication 
for surgery; (2) proper evaluation of  the patient based 
on factors predictive of  ovarian reserve [i.e., age, anti-
Müllerian hormone (AMH), antral follicle count]; and 
(3) surgery that is as minimally destructive of  the radical 
pelvic anatomy as possible. 
FERTILITY IN INFERTILE COUPLES
The purpose of  this section is to evaluate the effects of  
the IBDs in the infertile couple. In particular, our atten-
tion focused on reproductive outcomes (i.e., all intermedi-
ate steps and final results) of  an infertile couple in which 
one or both partners are affected by IBDs. Both CD 
and UC mainly affect young adults of  reproductive age. 
Whereas substantial data are available concerning preg-
nancy in young IBD women or fertility in IBD men, no 
study has been conducted on IBDs in infertile couples. 
In the few last years, only two studies[26,27] investigated 
the ovarian reserve status in CD women, as reflected 
by serum AMH. The first study[26] showed that women 
with CD do not have severe ovarian reserve alterations 
compared with a control population. However, age ≥ 
30 years and a colonic location of  the disease could be 
associated with an accelerated loss of  follicles. Another 
study[27] confirmed that serum AMH levels of  reproduc-
tive-age women with CD were significantly lower com-
pared with the controls, and the Crohn’s Disease Activity 
Index (CDAI) and AMH were inversely correlated. Thus, 
these data could encourage gastroenterologists to inform 
CD women of  the risk of  delaying childbirth.
Finally, only one report[28] described the reproduc-
tive outcome following intracytoplasmic sperm injection 
(ICSI) for male factor infertility associated with CD and 
6-mercaptopurine (6-MP) chemotherapy. The authors[28] 
reported the first successful birth after ICSI for severe 
oligozoospermia associated with CD. 
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birth weight[32,42]. Overall pregnancy outcomes in women 
with IBDs (CD or UC) were similar to those of  non-IBD 
pregnant patients[31].
A meta-analysis[43], including 3907 subjects, reported 
increased risks for preterm delivery (OR = 1.87, 95%CI: 
1.52-2.31) in both CD and UC patients; low birth weight 
(OR = 2.82, 95%CI: 1.42-5.60) in CD but not in UC; and 
congenital abnormalities (OR = 3.88, 95%CI: 1.14-10.67) 
in UC but not in CD. A Swedish population study found 
4.5% and 1.2% of  children born to IBD patients had, 
respectively, low and very low birth weight, as compared 
to 2.9% and 0.6% in the overall Swedish population[44]. 
Moser et al[32] additionally found an increased incidence 
of  poor maternal weight gain during pregnancy in CD 
patients with quiescent disease at conception.
In both CD and UC patients, pregnancies ended more 
frequently with caesarean section compared with the gen-
eral population[45]. Furthermore, pregnant CD and UC 
patients who needed to be hospitalized had a higher risk 
of  undergoing a caesarean section (OR = 1.72, 95%CI: 
1.44-2.04 and OR = 1.29, 95%CI: 1.01-1.66, respectively) 
in comparison with patients without IBD[46].
Prevention and treatment of IBDs during pregnancy
Most of  the drugs used to treat IBD are not associated 
with increased risk of  congenital anomalies or adverse ef-
fects on the fetus (Table 1). The 2010 European Crohn´s 
and Colitis Organisation (ECCO) guidelines state “medi-
cal treatment for Crohn’s disease (except methotrexate) 
should generally continue during pregnancy, because the 
benefits outweigh the risks of  medication”[46]. Moreover, 
as complications and adverse pregnancy outcomes mainly 
occur in patients with active disease, the main concern 
should be to achieve remission before conception and 
maintain quiescent disease during pregnancy. Patients 
who received counseling regarding the benefits and risks 
of  drug treatment before conception and during preg-
nancy were more likely to remain compliant[34].
It is generally regarded as safe to keep using amino-
salicylates (ASA) during pregnancy [Food and Drugs 
Administration (FDA) category B drug], despite some 
reports noting a higher incidence of  neural tube defects, 
oral cleft and cardiovascular defects[47]. In a recent meta-
analysis of  treatment of  IBD patients with 5-ASA drugs, 
IBD did not significantly increase the risk of  congenital 
abnormalities (OR = 1.16), stillbirth (OR = 2.38), spon-
taneous abortion (OR = 1.14), preterm delivery (OR = 
1.35) or low birth weight (OR = 0.93)[48].
Several studies[49,50] reported that sulfasalazine assump-
tion during pregnancy does not give rise to increased 
rates of  birth defects in women with IBD. Sulfasalazine 
therapy should be accompanied by extra folate supple-
mentation, as this medication halts folate synthesis by 
inhibiting dihydrofolate reductase. Folic acid supplemen-
tation decreases the augmented risk of  oral clefts and 
cardiovascular anomalies associated with folate antagonist 
treatment during pregnancy[51]. Caution should be applied 
regarding the use of  some mesalamine formulations (e.g., 
PREGNANCY
Several recent data are available in literature on IBDs and 
pregnancy. However, the majority of  published studies 
are reviews or retrospective analyses.
Effects of pregnancy on IBDs disease activity
Pregnancy seems to have a beneficial effect on IBD 
symptoms, especially when it occurs during disease re-
mission. A small, but significant, decrease in the Harvey-
Bradshaw index of  disease activity during pregnancy, in 
comparison with the year preceding and following preg-
nancy, was observed in a retrospective analysis on women 
with CD[29]. Similar results were found in a large Europe-
an prospective study, showing that 74% of  CD and 67% 
of  UC patients with active disease at conception achieved 
remission later during pregnancy[30].
Factors affecting remission or exacerbation of  IBDs 
have been investigated extensively. In particular, smok-
ing has a negative effect on the course of  CD, and some 
authors showed that the reduced disease activity in preg-
nancy was partly the result of  reduced tobacco smoking 
during pregnancy[31]. By contrast, exacerbation of  disease, 
particularly in the first trimester of  pregnancy, could re-
sult from discontinuation of  maintenance therapy.
The state of  the disease at conception is a factor in-
fluencing the course of  pregnancy[32-34]. In fact, patients 
with active disease at conception often continue to have 
symptoms during pregnancy, whereas a normal course 
of  pregnancy can be expected in patients who conceive 
when in remission. In a cohort study with a 10-year 
follow-up period, it was observed that if  conception oc-
curred during remission, the risk of  a flare-up was com-
parable to that in non-pregnant patients with IBD. In-
stead, when conception occurred during an active disease 
period, two-thirds of  patients relapsed during pregnancy 
and more than 60% of  these patients experienced further 
deterioration[35].
The course of  IBD in the postpartum period remains 
controversial. A small prospective study reported a de-
crease in relapse rate in CD, as well as in UC patients, 
4 years after pregnancy, in comparison with the 3 years 
before pregnancy[36]. Similarly, in a large cohort study, the 
yearly flare-up rates decreased from 0.34 to 0.18 in UC 
and from 0.76 to 0.12 in CD. Two studies[37,38] also report-
ed reduced stenosis and resection rates in women with 
IBD after pregnancy. Mechanisms potentially involved 
could be related to the hormone relaxin, the effect of  
pregnancy on the immune response, as well as feto-ma-
ternal HLA disparity[38,39]. The effects of  breastfeeding on 
flare-up rates in IBD mothers are also controversial[40,41]. 
Effect of IBDs on pregnancy/perinatal outcomes
Current data indicate that quiescent disease has minimal 
impact on the course and outcome of  pregnancy in IBD 
patients, whereas patients with active disease at concep-
tion have increased rates of  spontaneous abortion[33] and 
a significantly increased risk of  preterm delivery and low 
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asacol) that contain dibutyl phthalate (DBP) as a coating 
agent. The use of  DBP-coated medications produces 
measurable phthalate metabolite levels in urine. Prenatal 
exposure to DBP can cause congenital malformations in 
the male urogenital tract[52]. Finally, the sulfasalazine me-
tabolite sulfapyridine is secreted into breast milk. ASA are 
generally considered safe during lactation, although a case 
of  bloody diarrhea in an infant has been reported[53-55].
The use of  antibiotics during pregnancy, i.e., matroni-
daole and quinolones, should be considered with cau-
tion. Metronidazole is considered a low-risk drug during 
pregnancy (FDA class B). While several studies did not 
find an association between metronidazole treatment 
and birth defects[56], a large case-control study showed 
an increased incidence of  cleft lip and/or cleft palate in 
infants of  mothers exposed to metronidazole in the first 
trimester of  pregnancy[57]. Thus, it should be limited to 
short-term use for the treatment of  pouchitis. In addi-
tion, as metronidazole is excreted in breast milk, breast-
feeding during its administration is not recommended[56].
Quinolone antibiotics are FDA category C drugs and 
should be avoided because they carry an increased risk of  
arthropathy because of  their high affinity for bone and 
cartilage. ECCO recommends avoiding quinolone use in 
the first trimester of  pregnancy[57]. Data on breastfeed-
ing are limited, but quinolone use is probably compatible 
with breastfeeding[58,59].
The recent London position statement on biological 
therapy for IBD states that anti-tumor necrosis factor 
(TNF) therapy is considered low risk and can be used 
in the preconception period and during the first two tri-
mesters of  pregnancy[60]. The cytokine TNF-α not only 
plays a pivotal role in the inflammation process underly-
ing IBD, but also plays physiological roles in host defense 
mechanisms and pregnancy. During pregnancy, TNF-
αprobably plays a role in protecting the fetus against tera-
togenic stress[61]. Despite the role of  TNF in pregnancy, 
treatment with anti-TNF antibodies can be considered 
safe in the preconception period and the first part of  
pregnancy, because IgG antibodies do not cross the pla-
centa in the first pregnancy trimester and transplacental 
IgG transport mainly takes place during the late second 
and third trimester of  pregnancy[62,63]. Maternal transfer 
of  IgG during the last trimester of  pregnancy provides 
the neonate with sufficient acquired immunity to defend 
itself  while its own immune system is becoming fully 
functional. 
The currently available TNF inhibitors (etanercept, 
infliximab, adalimumab, golimumab and certolizumab) 
are all classified as FDA category B drugs, indicating 
that no teratogenic effects of  these drugs were observed 
in animal reproduction studies; however, adequate and 
controlled human safety data are still lacking. Transfer 
of  anti-TNF antibodies to the fetus during the last part 
of  pregnancy may mean exposure of  the neonate in the 
first months after birth, raising potential concerns about 
infection and response to vaccines[60].
Infants exposed to immunosuppressive drugs during 
pregnancy probably should be considered to be immu-
nocompromised, as are their mothers. ECCO guidelines 
state that live vaccinations (BCG, rotavirus, mumps-
measles-rubella (MMR) and varicella zoster) are contrain-
dicated until exposure to immunosuppressants has been 
discontinued for at least 3 mo[64]. IgA is the predominant 
immunoglobulin in human milk, so secretion of  TNF in-
hibitors in milk is likely to be very limited and breastfeed-
ing under anti-TNF treatment can be considered safe[65].
Natalizumab is an α-4 integrin inhibitor approved 
for treatment of  CD in the US, but not in Europe. Ex-
perience with natalizumab in the context of  IBD is still 
limited, even if  this biological compound is widely used 
for treating multiple sclerosis. It has received an FDA 
category C label. Thus, at present insufficient data are 
available to reach a definite conclusion on the safety of  
natalizumab during pregnancy and lactation.
Corticosteroids are FDA category C drugs. They are 
7127 June 21, 2014|Volume 20|Issue 23|WJG|www.wjgnet.com
Table 1  Safety indications for drugs in pregnancy and breastfeeding
UC ECCO rating 
pregnancy
ECCO rating 
breastfeeding
Personal observations
5-ASA 
(except sulfasalazine)
B Safe Safe Avoid high doses for long time, asacol preparations may be switched 
to another mesalamine
Sulfasalazine B Safe Safe Folate supplements are required
AZA/6-MP D Safe Probably safe Discuss breastfeeding with the patient. Avoid lactation in the four 
hours after intake of the drug
Cyclosporine A C Probably safe Contraindicated Use only in severe cases of UC to avoid urgent colectomy during 
pregnancy
Methotrexate X Contraindicated Contraindicated Discontinue at least 4 mo prior to conception
Corticosteroids C Safe Safe Very low risk of malformations. If possible, not use for long time
Infliximab B Probably safe Safe Can be used safely in the first two trimesters of pregnancy. If possible, 
avoid in the third trimester
Adalimumab B Probably safe No data Can be used safely in the first two trimesters of pregnancy. If possible, 
avoid in the third trimester
Metronidazole B Probably safe Best avoided Very slight increase of cleft lip. Use only if strictly necessary
Ciprofloxacin C Probably safe Probably safe Use only for short periods and avoid in the first trimester
Thalidomide X Contraindicated Contraindicated
5-ASA: 5-aminosalicylates; AZA: Azathioprine; 6-MP: 6-mercaptopurine; ECCO: European Crohn’s Colitis Organisation; UC: Ulcerative colitis.
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believed to be safe throughout pregnancy at doses up to 
15 mg per day[60], whereas higher doses increase the risk 
of  infection and premature delivery[66]. Systemic treat-
ment with corticosteroids during the first trimester of  
pregnancy was found to slightly increase the risk of  oral 
clefts (OR = 3.35, 95%CI: 1.97-5.69), while the overall 
risk of  congenital malformations is not significantly in-
creased (OR = 1.45, 95%CI: 0.80-2.60)[67].
Pregnant women are preferably treated with predni-
sone or prednisolone, as the bulk of  these compounds 
are inactivated by placental 11β-hydroxy steroid dehydro-
genase, the physiological mechanism in place to protect 
the fetus from elevated maternal cortisol levels during 
pregnancy. Treatment with corticosteroids is compatible 
with breastfeeding[68,69].
Cyclosporine crosses the placenta but is rapidly 
cleared in the neonate and has no known teratogenic ef-
fect. FDA categorizes cyclosporine in pregnancy category 
C for lack of  controlled studies in humans; however, cy-
closporine does not appear to be a major teratogen.
A meta-analysis[58] on the use of  cyclosporine in preg-
nancy showed that cyclosporine use in pregnancy was 
not associated with major malformations, but slightly 
decreased birth weight and duration of  gestation. In IBD 
patients, cyclosporine use in refractory UC during preg-
nancy has been shown to be safe and effective. Its main 
use in pregnant IBD patients is the prevention of  urgent 
colectomy in fulminant UC[70,71].
Although a number of  cases are reported where no 
overt adverse effects were observed in breastfed infants 
of  mothers treated with cyclosporine, the use of  this 
drug during lactation is generally not advised as cyclo-
sporine is secreted in milk at high concentrations, leading 
to potential nephrotoxicity and immunosuppression in 
exposed infants[72].
ASA and 6-MP are still designated as FDA category 
D drugs, indicating that increased risk for the fetus exists, 
but the risk must be weighed against the possible benefits 
of  the drug. A recent Danish cohort study showed an 
increased risk of  preterm delivery and low birth weight in 
women exposed to azathioprine (AZA) or 6-MP during 
pregnancy, but no significant increase in congenital mal-
formations[50].
The CESAME study[73], a cohort study comparing 
IBD patients exposed to thiopurine therapy during preg-
nancy with women receiving other treatments or women 
without any drug therapy, showed that thiopurine expo-
sure was not associated with low birth weight prematurity 
and congenital abnormalities, but was associated with 
preterm birth. Exposure in men at the time of  concep-
tion was not associated with congenital abnormalities[74]. 
Thiopurine treatment is generally considered a contrain-
dication for breastfeeding.
Methotrexate has teratogenic properties and is con-
traindicated during pregnancy (FDA category X). Metho-
trexate metabolites have long tissue half-lives; therefore, 
its administration must be stopped 3 to 6 mo before con-
ception[75]. Folic acid supplementation after methotrexate 
withdrawal is also recommended because methotrexate 
acts as a folate antagonist. Methotrexate is also contrain-
dicated during lactation because of  its potential accumu-
lation in the child’s tissues.
Thalidomide and its analog lenalidomide partly coun-
teract the effects of  TNF-α and have been used in pa-
tients with refractory CD, even if  currently available sys-
tematic evidence does not clearly demonstrate the benefit 
of  these drugs[76]. The teratogenicity of  these drugs has 
been well documented, indicating increased risks for limb 
defects, central nervous system defects, and congenital 
abnormalities in the cardiovascular, respiratory, gastro-
intestinal, and genitourinary tracts. Thus, thalidomide is 
absolutely contraindicated in pregnancy (FDA category 
X) and patients taking thalidomide are advised to use two 
complementary contraceptive methods[77,78]. Although le-
nalidomide appears less teratogenic in animal studies, the 
lack of  studies demonstrating its safety in humans leads 
to the absolute contraindication of  this drug in pregnant 
patients or in patients wishing to become pregnant[77,78].
Management of delivery in women with IBDs
Pregnancy should not be considered high risk in all cases 
of  IBDs. Delivery, therefore, can be carried out in clin-
ics of  the second or third level. Only patients with active 
IBD necessitating steroid and/or anti-TNF treatment, 
patients with ileostomies, and patients with ileoanal 
pouches should be referred to high-risk pregnancy clinics.
Active perianal disease at the time of  delivery is an 
indication for caesarean section, whereas patients without 
history of  perianal disease or inactive perianal disease 
do not require caesarean delivery[45]. In UC patients with 
IPAA, caesarean section rates of  almost 50% have been 
reported, but the incidence of  pouch-related complica-
tions was low and pouch function was found to be un-
related to the mode of  delivery[79]. However, the most 
recent ECCO guidelines state that the presence of  an 
ileoanal pouch in CD patients is an indication for cae-
sarean section[80]. Moreover, patients with IPAA surgery 
in the past are always advised to have caesarean section, 
and we recommend that an abdominal surgeon should be 
present during the surgery.
MALE FERTILITY
Clinical data
Infertility in men with IBD has been relatively less stud-
ied than infertility in women with IBD. A recent Euro-
pean consensus states that both male and female fertility 
are not significantly affected in non-operated IBD pa-
tients when disease is quiescent, compared to the general 
population[81]. It is important to note that IBD patients 
remain voluntarily childless more frequently than non-
IBD controls[82]. In a survey among 255 Australian IBD 
patients, fear concerning IBD heritability, side effects of  
the medication on the child, and medical advice given by 
physicians were the most important reasons for voluntary 
childlessness[13].
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A recent systematic review[83] on fertility in non-surgi-
cally treated IBD showed that in men with CD (a total of  
493 men in two population-based and one referral center 
studies), there was an 18%-50% reduction in fertility 
compared with controls, although whether the cause was 
involuntary infertility or voluntary childlessness was not 
indicated. There was no evidence of  reduced fertility in 
men with UC[83].
IBD and male fertility intermediate end-points
Active disease, IBD treatment, and psychological factors 
affect male reproductive and sexual function[84]. Most 
male IBD patients considered “maintaining remission” 
as important at conception[85] and in fact inflammation 
has a negative effect on male fertility[86]. Men who were in 
remission or who had only mild disease activity had rates 
of  erectile dysfunction similar to those of  healthy control 
subjects, whereas men with more severe IBD activity had 
higher rates[87].
IBD and semen parameters
There are no large studies that assess semen abnormali-
ties in IBD patients on no medication at all. Some studies 
suggest that factors such as disease activity and nutrition-
al status could affect semen[88-90]. Furthermore, there are 
reports of  antisperm antibodies in both men and women 
with IBD, and these antibodies might contribute to in-
fertility. Antisperm antibodies might be a result of  the 
increased immunological response, caused by increased 
intestinal permeability, against antigens of  gut microbiota 
possessing common antigenicity with spermatozoa[91]. 
Dimitrova et al[92] showed that antisperm antibody inci-
dence in 50 patients with ulcerative colitis was statistically 
significant compared with 50 healthy blood donors[92]. A 
little study on 10 IBD patients (four women and six men) 
and reported the presence of  antisperm antibodies in se-
men of  male patients and cervical secretions of  female 
patients at the time of  ovulation[93].
Surgery and male fertility
The most common surgery in IBD patients is IPAA. 
Proctocolectomy with IPAA has been associated with 
sexual dysfunction in men. A large study found 1% and 
2% of  sexual dysfunction at 1 year and 12 years after sur-
gery, respectively[94]. Furthermore, 3% of  men reported 
experiencing either retrograde ejaculation or no ejacula-
tion 10 years after surgery[94]. 
A meta-analysis of  43 observational studies that 
evaluated patients after IPAA found the pooled inci-
dence of  sexual dysfunction to be 3.6%[95]. On the other 
hand, a study of  122 men who had undergone IPAA 
evaluated male sexual function using a validated index 
based on erectile function, orgasmic function, sexual 
desire, intercourse satisfaction and overall satisfaction[96]. 
This study showed that, despite any negative effect on 
erectile function (in particular retrograde ejaculation), 
the other four features had a statistically significant im-
provement[96]. A Dutch study confirmed that despite an 
elevated rate of  sexual dysfunction of  up to 25% in 35 
men after IPAA for UC, 90% of  patients were satisfied 
with the operation[97].
A randomized, placebo-controlled trial of  sildenafil 
for erectile dysfunction following rectal excision per-
formed either for cancer or IBD in 32 men showed that 
post-operative sexual dysfunction can be treated success-
fully with sildenafil in most cases (79% of  the sildenafil-
treated group compared to only 17% of  the group taking 
placebo)[98].
There are other types of  surgery beyond IPAA, for 
example, total colectomy with end ileostomy, colectomy 
with ileo-rectal anastomosis, and proctocolectomy with 
ileo-anal anastomosis without a pouch. The reports on 
sexual function after these procedures are limited, but 
only ileo-rectal anastomosis avoids the extensive pelvic 
dissection of  the other procedures, which produces ad-
verse effects on sexual function.
Medical treatments and male fertility
Table 2 shows the effects of  IBD medications on erec-
tile dysfunction, infertility and pregnancy. In the general 
population, medications are responsible for erectile dys-
function in up to 25% of  cases[99]. The medications used 
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Table 2  Effects of inflammatory bowel disease medications on erectile dysfunction, male infertility and partner’s pregnancy
Erectile 
dysfunction
Infertility Pregnancy 
complications
Recommendations 
5-ASA (except sulfasalazine) No Single reversible case No reports No recommendations to discontinue prior to 
conception
Sulfasalazine Single case Yes, reversible, not dose 
dependent
One study Switch to other 5-ASA preparations
AZA/6-MP No reports No Controversial No recommendations to discontinue prior to 
conception
Cyclosporine A No reports No No reports No recommendations to discontinue prior to 
conception
Methotrexate Yes Controversial No reports Discontinue 3-4 mo prior to conception
Steroids No reports No No reports Lack of data to discontinue
TNF-α inhibitors 
(infliximab, and only a case report for adalimumab)
No reports Reduce sperm quality, 
but no infertility
No No recommendations to discontinue prior 
to conception, but barrier methods during 
pregnancy
5-ASA: 5-aminosalicylates; AZA: Azathioprine; 6-MP: 6-mercaptopurine; TNF: Tumor necrosis factor. 
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to treat IBD rarely cause erectly dysfunction; however, 
antidepressants and anti-anxiety medications, frequently 
prescribed for patients with IBD, could cause erectile 
dysfunction because depressive mood negatively influ-
ences sexual function (patients with a first diagnosis of  
IBD had higher rates of  depression than patients with 
diagnosis of  colon cancer)[100].
On the other hand, many drugs have been reported 
to impair semen parameters; sulfasalazine, methotrex-
ate, and infliximab seem to affect sperm quality[57]. Of  
note, confounding factors that could affect male fertility, 
such as smoking, alcohol consumption, disease status, 
and medication use, are not always reported in studies 
investigating the effects of  medical treatments on male 
fertility. Men with IBD rarely have documented physician 
counseling regarding the potential effects of  medication 
on fertility and pregnancy because gastroenterologists’ 
lack of  knowledge of  the effects of  medications on male 
fertility or a lack of  documentation of  their counselling 
practices[101].
Except for sulfasalzine, the risk of  adverse fetal out-
comes of  other medications must be weighed against the 
benefit of  maintaining good health of  the father at the 
time of  conception.
The only 5-ASA medication shown to cause male in-
fertility is sulfasalazine[102,103]. Sulfasalazine causes revers-
ible non-dose-dependent semen abnormalities (oligosper-
mia, reduced motility and abnormal morphology)[104,105] 
and infertility in up to 60% of  men[106]. Impaired sperm 
maturation and oxidative stress from the sulfapyridine 
constituent of  the drug are thought to be the cause[107-110]. 
Male fertility is restored two months after sulfasalazine 
withdrawal or switching to other mesalazine prepara-
tions[111-115]. A single case of  impotence was reported that 
was resolved after switching to olsalazine[116]. One study 
found an association between sulfasalazine use in men 
and a higher rate of  congenital malformations in their 
children[106]. There is a single case report of  mesalazine-
induced oligospermia and infertility that reversed when 
the drug was stopped[117]. Given these data, no recom-
mendations are made to discontinue 5-ASA (except sul-
fasalazine) for men planning to conceive. 
A study of  18 men with IBD showed that AZA 
did not reduce semen quality, and thus male fertility, in 
IBD: no changes in semen parameters were noted after 
11 ± 5 mo of  AZA administration or during long-term 
treatment (49 ± 14 mo)[118]. In a survey of  164 male 
renal transplant patients, long-term therapy with cyclo-
sporine, AZA and prednisone demonstrated no effects 
on fertility[119].
The teratogenic effect of  AZA and its metabolite 
6-MP remains controversial. In one retrospective study, 
the incidence of  pregnancy-related complications was 
significantly increased when the fathers used 6-MP within 
3 mo of  conception[120]. Specifically, in men with IBD 
under 6-MP, congenital anomalies and spontaneous abor-
tions were detected in 4% and 6% of  cases, respectively. 
These data are substantially different from those ob-
served in men with IBD who were not taking this drug 
(no congenital anomalies and 2% of  spontaneous abor-
tions)[120]. However, the rates of  congenital abnormali-
ties and spontaneous abortions were below those of  the 
general population - 3% and 10%, respectively[121]. In a 
Danish population-based cohort study, the paternal use 
of  AZA or 6-MP before conception was associated with 
an increased, but not statistically significant, risk of  con-
genital abnormalities[122]. 
Two other studies did not observe any significant ef-
fect of  preconception thiopurine exposure of  the father 
on pregnancy outcomes. Francella et al[123] showed that 
there was no statistical difference in conception failures 
(defined as a spontaneous abortion), abortion secondary 
to a birth defect, major congenital malformations, neo-
plasia or increased infections among offspring of  male 
patients taking 6-MP compared with controls. In 2010, 
Teruel et al[124] confirmed there were no significant differ-
ences in terms of  unsuccessful pregnancies between the 
exposed group (MP 9, AZA 37) and the control group. 
Given these data, no recommendations are made to dis-
continue AZA/6-MP for men planning to conceive.
There are no data regarding the effects of  cyclospo-
rine on fertility of  men with IBD. In animal models, 
cyclosporine A causes damage of  testicular tissue and 
sperms[125], but antioxidants may protect from testicular 
toxicity[126,127]. In humans, the small studies conducted do 
not seem to suggest any association between cyclospo-
rine and male infertility: a decrease in serum antisperm 
antibodies[128,129], normal semen analysis, and successful 
pregnancies are described[130]. There are no reports of  ad-
verse pregnancy among partners of  men who were taking 
cyclosporine. No recommendations are made to discon-
tinue cyclosporine A for men planning to conceive.
Methotrexate is the one most often associated with 
impotence[131-133]. However, few data are available on the 
effects of  methotrexate on male reproductive capability. 
In animal models, it causes altered spermatogenesis and 
degeneration of  spermatocytes, Sertoli cells, and Leydig 
cells[134-136]. Opinions differ in the literature on the ef-
fects of  methotrexate on male fertility: the concurrent 
administration of  other chemotherapeutic agents is a 
limitation[137].
There are small studies reporting on methotrexate use 
with no other agents. In patients affected by psoriasis, 
there are cases of  documented reversible sterility when 
the methotrexate was stopped[138] and there are several 
case series that report no change in sperm quality[139-142]. 
There are no reports of  adverse pregnancy outcomes 
among the partners of  men exposed to methotrexate 
before conception[143]. However, the active metabolites 
of  methotrexate can remain in cells or tissues for several 
months after discontinuation[144]. Given these data, it is 
recommended that the drug should be discontinued at 
least 3-4 mo before attempts at conception for men with 
IBD[145-147].
Few data are available on the effects of  steroid 
therapy on male fertility[118,148]: it appears there is little 
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impact. Although steroids may inhibit apoptosis of  dam-
aged sperm cells, they may prevent pathological excessive 
apoptosis, which results in oligospermia[149]. No recom-
mendations can be made to discontinue steroid use due 
to insufficient data.
There are few studies also on the effects of  anti-tu-
mor necrosis factor agents; the data do suggest, however, 
that these medications may impair male fertility. Inflix-
imab may also serve to counter the negative effects of  
TNF-α on sperm quality[150]: supraphysiological levels of  
TNF-α were seen to cause chromatin and DNA damage, 
and reduce sperm motility[151]. Reports on male fertility 
in ankylosing spondylitis patients showed a decrease in 
sperm motility in patients on conventional treatment vs 
anti-TNF-α-treated patients[152].
In a study of  10 men, infliximab increased semen 
volume with a trend towards decreased sperm motility 
and morphology, but its impact on male fertility was not 
reported[153]. Villinger et al[154] showed sperm abnormali-
ties that were more pronounced in patients with active 
spondyloarthritis, but the sperm quality of  patients with 
inactive disease receiving long-term TNF inhibition is 
comparable to that in healthy controls. Another report 
on four patients with ankylosing spondylitis who fathered 
six healthy children during infliximab treatment may pro-
vide some reassurance for male patients treated with in-
fliximab[155]. The data support continuation of  anti-TNF 
treatment when IBD patients plan fatherhood[154].
The recent Austrian evidence-based consensus on the 
safe use of  infliximab in inflammatory bowel disease[156] 
states that infliximab may lead to reduced quality by de-
creasing sperm motility and affecting sperm morphology, 
although these findings do not demonstrate that male 
fertility would be reduced[157].
Infliximab treatment of  men prior to planned con-
ception does not seem to cause embryo toxicity. For anti-
TNF alpha, as it is unknown whether the fetus will be 
affected by exposure to anti-TNF alpha through semen, 
the ECCO consensus on reproduction in IBD advises 
barrier methods during pregnancy. Data on the impact 
of  other biologicals on male fertility are currently lacking, 
although there is a case report of  35-year-old father of  a 
healthy 4-year-old child who was successfully treated for 
3 years with adalimumab for ankylosing spondylitis[158]. 
No recommendations are made to discontinue anti-
TNF-α treatment for men planning to conceive.
CONCLUSION
IBDs significantly affect several reproductive aspects of  
human (female, male, couple) reproduction. Moreover, 
further data are needed in order to develop guidelines 
for the clinical management of  subjects of  reproduc-
tive age with IBDs. In fact, at the moment, there are no 
established guidelines for the preservation of  fertility in 
women with IBD undergoing surgery. Further data are 
needed regarding the management of  these patients.
Data regarding IBDs and infertility are currently com-
pletely lacking. Considering the prevalence of  intestinal 
pathology in young adults of  childbearing age, this field is 
of  great scientific and clinical interest, opening up impor-
tant future perspectives. Further studies should, in fact, 
be conducted to determine whether the treatments for 
infertility have an effect on the state of  IBD (remission, 
flare-up, recurrence). Another important point as yet 
unexplored is the response to treatments for infertility in 
patients with IBDs. In particular, the question is whether 
the reproductive outcomes (clinical and biological) can be 
influenced by the IBD of  one of  the partners.
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